| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $480K | — | +62.1% |
| R&D Expense | $2.1M | — | +5.7% |
| SG&A Expense | $2.8M | — | +7.2% |
| Operating Income | -$4.5M | — | -2.3% |
| Pre-tax Income | -$4.5M | — | -2.9% |
| Net Income | -$4.5M | — | -2.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $339K | +41.8% | -67.1% |
| Current Assets | $2.1M | -62.4% | -62.1% |
| Total Assets | $6.4M | -35.5% | -35.4% |
| Current Liabilities | $1.2M | -8.5% | -46.9% |
| Total Liabilities | $1.2M | -8.5% | -46.9% |
| Stockholders' Equity | $5.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.4M | — | +36.2% |
| Investing Cash Flow | -$2K | — | +0.0% |
| Financing Cash Flow | -$245K | — | +0.0% |
| -31.8% |